| 12.58 -0.23 (-1.8%) | 04-24 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 17.76  |
1-year : | 20.27 |
| Resists | First : | 15.2 |
Second : | 17.36 |
| Pivot price | 13.59 |
|||
| Supports | First : | 11.72 | Second : | 9.75 |
| MAs | MA(5) : | 12.5  |
MA(20) : | 14.12 |
| MA(100) : | 15.4 |
MA(250) : | 14.69 |
|
| MACD | MACD : | -1.1 |
Signal : | -1 |
| %K %D | K(14,3) : | 26.7 |
D(3) : | 21 |
| RSI | RSI(14): 35.5 |
|||
| 52-week | High : | 20.21 | Low : | 9.93 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ HLVX ] has closed above bottom band by 25.1%. Bollinger Bands are 41.6% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 5 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 12.85 - 12.93 | 12.93 - 13 |
| Low: | 12.31 - 12.39 | 12.39 - 12.46 |
| Close: | 12.46 - 12.59 | 12.59 - 12.71 |
HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines. It is developing HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company is headquartered in Boston, Massachusetts.
Mon, 22 Apr 2024
HilleVax (NASDAQ:HLVX) Shares Up 6.3% - MarketBeat
Tue, 16 Apr 2024
HilleVax, Inc. (NASDAQ:HLVX) Short Interest Down 5.6% in March - MarketBeat
Thu, 11 Apr 2024
HilleVax (NASDAQ:HLVX) Shares Up 3.2% - MarketBeat
Mon, 08 Apr 2024
HilleVax, Inc. (NASDAQ:HLVX) Major Shareholder Life Sciences X. L.P. Frazier Buys 8,850 Shares - MarketBeat
Sat, 06 Apr 2024
Director Aditya Kohli Sells 18,000 Shares of HilleVax Inc (HLVX) - Yahoo Finance
Fri, 22 Mar 2024
HilleVax: Mid-2024 Data Is Crucial Inflection Point For Continued Valuation (NASDAQ:HLVX) - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 50 (M) |
| Shares Float | 23 (M) |
| Held by Insiders | 5.7 (%) |
| Held by Institutions | 76.5 (%) |
| Shares Short | 448 (K) |
| Shares Short P.Month | 431 (K) |
| EPS | -3.04 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 5.65 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -25.2 % |
| Return on Equity (ttm) | -46.4 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -2.67 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -87 (M) |
| Levered Free Cash Flow | -62 (M) |
| PE Ratio | -4.14 |
| PEG Ratio | 0 |
| Price to Book value | 2.22 |
| Price to Sales | 0 |
| Price to Cash Flow | -7.21 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|